Overview of the Study
Clinical trials evaluating treatments for patients with head and neck squamous cell carcinoma (HNSCC) are frequently terminated before completion — and the reasons go far beyond scientific failure. A new retrospective study from researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, found that strategic sponsor decisions and poor patient recruitment are the dominant drivers of trial failure in this cancer indication. The study was published in JAMA Otolaryngology–Head & Neck Surgery.
The findings highlight a critical and often overlooked issue: trials that are terminated or withdrawn never reach their endpoints, representing a significant loss of resources, time, and potentially life-saving therapies for patients with HNSCC.
Key Findings on Trial Failure
Of 692 matched trials analyzed in the study, exactly half — 346 — failed, while the other 346 were completed. Among the failed trials, the leading causes were:
- Sponsor-driven strategic decisions (29.5%)
- Poor patient recruitment (26.0%)
When broken down by trial phase, the patterns became even more telling. Strategic decisions were the most common reason for failure in phase 1 trials (42.3%; 47 of 111 trials). Poor recruitment, however, dominated as the primary failure cause across later phases — phase 2 (30.0%; 57 of 190), phase 3 (22.0%; 9 of 41), and phase 4 (100%; 4 of 4).
“Classically, when we speak about clinical trial failures, we equate a failure to not reaching a primary end point or not reaching FDA approval,” the research team stated. “We sought to focus on the understudied and significant portion of trials that are terminated and withdrawn. These trials do not reach the finish line and therefore represent a significant loss of resources and potentially beneficial clinical therapies.”
How the Analysis Was Conducted
The cross-sectional case-control study identified interventional clinical trials for HNSCC treatment conducted between January 1, 2000, and December 31, 2024, using ClinicalTrials.gov. Failed studies were defined as those with terminated or withdrawn status and were matched with completed study controls through a 1:1 nearest-neighbor propensity score method based on trial phase.
The research team — comprised of Elizabeth J. Franzmann, MD, FACS; Alex Reznik, MD, PhD; and Janice Huang, MD, PhD — designed the study to uncover actionable insights into trial characteristics associated with failure. “We reasoned this could help the targeted design of trials that would avoid these pitfalls,” the team explained.
Factors Predicting Early Trial Failure
A multivariable logistic regression analysis identified several independent predictors of early trial failure in HNSCC:
Protective factors (associated with reduced failure risk):
- Higher enrollment numbers — increased log-transformed enrollment was protective (OR 0.36; 95% CI, 0.30–0.42)
- Government funding — industry-funded trials showed a significantly higher termination risk compared to government-funded ones (OR 2.84; 95% CI, 1.16–7.17)
Risk factors (associated with increased failure risk):
- Advanced trial phase — each phase progression increased termination odds (OR 1.81; 95% CI, 1.35–2.45)
- Inclusion of surgery or procedures — a strong predictor of failure (OR 1.98; 95% CI, 1.12–3.54)
By treatment type, strategic decisions were the most common failure reason for immunotherapy trials (54.8%; 46 of 84) and targeted therapy trials (27.4%; 17 of 62), while poor recruitment was cited most frequently across other treatment categories.
What These Findings Mean for Future Trials
The study underscores the need for a more nuanced, proactive approach to clinical trial design in HNSCC. Rather than simply measuring success by endpoint achievement or FDA approval, the research team argues that the field must account for trials that never reach conclusion at all — and take deliberate steps to prevent premature termination.
For trials vulnerable to strategic or operational failure, the team recommends stronger site selection processes and enhanced data monitoring practices. For trials at risk of recruitment failure — particularly later-phase, non-industry-sponsored, and chemotherapy, radiation, or combination treatment trials — updated and targeted recruitment schemas are essential.
Recommendations From the Research Team
The researchers offered specific, actionable guidance for investigators based on trial type:
Phase 1 and industry-sponsored trials, as well as immunotherapy and targeted therapy trials, may benefit most from rigorous feasibility assessments before launch and the incorporation of adaptive trial designs that allow for greater flexibility as the study progresses.
Trials at risk of poor recruitment should explore updated enrollment strategies tailored to their specific patient population and treatment context.
Looking ahead, the team stressed the value of collaborative, multidisciplinary science. “Further studies driven by collaborative team science between otolaryngologists, oncologists, and oral oncologists are needed to help address the unmet needs of patients with head and neck cancer,” they noted. More thorough, evidence-based clinical trial analyses for the HNSCC indication could ultimately improve the likelihood of trial success and reduce the human and financial cost of premature termination.
